Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

Core Insights - Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases [1][3] - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, where CEO Nello Mainolfi will discuss the company's progress and milestones for 2025 [1] Company Overview - Kymera is pioneering targeted protein degradation (TPD) to create therapies for health issues that conventional treatments cannot effectively address [3] - The company has advanced its first degrader into clinical trials for immunological diseases and aims to build a leading pipeline of oral small molecule degraders [3] - Founded in 2016, Kymera has been recognized as one of Boston's top workplaces in recent years [3] Presentation Details - A live webcast of the presentation and Q&A session will be available on the company's website, with a replay archived after the event [2]